跳至主要内容
临床试验/JPRN-UMIN000027600
JPRN-UMIN000027600招募中未知

A pilot study to examine the safety of combination with selective COX2 inhibitor meloxicam before autologous peripheral blood stem cell harvest and the collection efficiency of hematopoietic stem cells - The safety of meloxicam before autologous PBSCH and the collection efficiency of hematopoietic stem cells

Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital0 个研究点目标入组 5 人开始时间: 2017年6月2日最近更新:
适应症

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 65years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Patients who are not eligible for apheresis 2)Allergy to meloxicam 3)Patients who cannot take medicine orally on the 10th day after the administration of the anticancer drug 4)Patients with bleeding tendency before treatment 5)Patients who are difficult to maintain platelets more than 20,000/mm3 even if appropriate measures such as platelet transfusion are done 6)Patients with active gastrointestinal ulcer 7)Patients with severe renal dysfunction (G3b or more in GFR classification) 8)Patients with aspirin-induced asthma or a history of aspirin-induced asthma 9)Inadequate condition as diagnosed by primary physician

研究者

相似试验